BioXgen Opens Community Investment Round for $9B Open Heart Surgery Solution

Got story updates? Submit your updates here. ›

BioXgen, a Tucson-based medical device company, has launched a community investment round to fund the development of its innovative solution for open heart surgery. The company's new minimally invasive procedure aims to address the $9 billion annual cost of traditional open heart surgeries, which can be risky, expensive, and require lengthy recovery times for patients.

Why it matters

Open heart surgery remains one of the most common and costly medical procedures in the United States, with over 500,000 operations performed each year. BioXgen's approach has the potential to dramatically improve patient outcomes and reduce the financial burden on the healthcare system.

The details

BioXgen's device utilizes a novel, minimally invasive approach that allows surgeons to access the heart through a small incision, rather than the traditional open-chest procedure. This reduces trauma, recovery time, and overall costs associated with open heart surgery. The company is now seeking community investment to accelerate the development and regulatory approval of its groundbreaking technology.

• BioXgen was founded in Tucson, Arizona in 2022.
• The company launched its community investment round on March 30, 2026.

What’s next

BioXgen plans to use the funds raised through the community investment round to complete clinical trials and secure regulatory approval for its open heart surgery device.